TY - JOUR
T1 - Study design, rationale and methods of the Revitalising Informal Settlements and their Environments (RISE) study
T2 - A cluster randomised controlled trial to evaluate environmental and human health impacts of a water-sensitive intervention in informal settlements in Indonesia and Fiji
AU - Leder, Karin
AU - Openshaw, John J.
AU - Allotey, Pascale
AU - Ansariadi, Ansariadi
AU - Barker, S. Fiona
AU - Burge, Kerrie
AU - Clasen, Thomas F.
AU - Chown, Steven L.
AU - Duffy, Grant A.
AU - Faber, Peter A.
AU - Fleming, Genie
AU - Forbes, Andrew B.
AU - French, Matthew
AU - Greening, Chris
AU - Henry, Rebekah
AU - Higginson, Ellen
AU - Johnston, David W.
AU - Lappan, Rachael
AU - Lin, Audrie
AU - Luby, Stephen P.
AU - McCarthy, David
AU - O'Toole, Joanne E.
AU - Ramirez-Lovering, Diego
AU - Reidpath, Daniel D.
AU - Simpson, Julie A.
AU - Sinharoy, Sheela S.
AU - Sweeney, Rohan
AU - Taruc, Ruzka R.
AU - Tela, Autiko
AU - Turagabeci, Amelia R.
AU - Wardani, Jane
AU - Wong, Tony
AU - Brown, Rebekah
N1 - Funding Information:
Funding This trial has been primarily funded by the Wellcome Trust 'Our Planet, Our Health' grant (205222/Z/16/Z). The intervention is funded by the Asian Development Bank, the New Zealand Ministry of Foreign Affairs and Trade, and Monash University.
Publisher Copyright:
©
PY - 2021/1/8
Y1 - 2021/1/8
N2 - Introduction Increasing urban populations have led to the growth of informal settlements, with contaminated environments linked to poor human health through a range of interlinked pathways. Here, we describe the design and methods for the Revitalising Informal Settlements and their Environments (RISE) study, a transdisciplinary randomised trial evaluating impacts of an intervention to upgrade urban informal settlements in two Asia-Pacific countries. Methods and analysis RISE is a cluster randomised controlled trial among 12 settlements in Makassar, Indonesia, and 12 in Suva, Fiji. Six settlements in each country have been randomised to receive the intervention at the outset; the remainder will serve as controls and be offered intervention delivery after trial completion. The intervention involves a water-sensitive approach, delivering site-specific, modular, decentralised infrastructure primarily aimed at improving health by decreasing exposure to environmental faecal contamination. Consenting households within each informal settlement site have been enrolled, with longitudinal assessment to involve health and well-being surveys, and human and environmental sampling. Primary outcomes will be evaluated in children under 5 years of age and include prevalence and diversity of gastrointestinal pathogens, abundance and diversity of antimicrobial resistance (AMR) genes in gastrointestinal microorganisms and markers of gastrointestinal inflammation. Diverse secondary outcomes include changes in microbial contamination; abundance and diversity of pathogens and AMR genes in environmental samples; impacts on ecological biodiversity and microclimates; mosquito vector abundance; anthropometric assessments, nutrition markers and systemic inflammation in children; caregiver-reported and self-reported health symptoms and healthcare utilisation; and measures of individual and community psychological, emotional and economic well-being. The study aims to provide proof-of-concept evidence to inform policies on upgrading of informal settlements to improve environments and human health and well-being. Ethics Study protocols have been approved by ethics boards at Monash University, Fiji National University and Hasanuddin University. Trial registration number ACTRN12618000633280; Pre-results.
AB - Introduction Increasing urban populations have led to the growth of informal settlements, with contaminated environments linked to poor human health through a range of interlinked pathways. Here, we describe the design and methods for the Revitalising Informal Settlements and their Environments (RISE) study, a transdisciplinary randomised trial evaluating impacts of an intervention to upgrade urban informal settlements in two Asia-Pacific countries. Methods and analysis RISE is a cluster randomised controlled trial among 12 settlements in Makassar, Indonesia, and 12 in Suva, Fiji. Six settlements in each country have been randomised to receive the intervention at the outset; the remainder will serve as controls and be offered intervention delivery after trial completion. The intervention involves a water-sensitive approach, delivering site-specific, modular, decentralised infrastructure primarily aimed at improving health by decreasing exposure to environmental faecal contamination. Consenting households within each informal settlement site have been enrolled, with longitudinal assessment to involve health and well-being surveys, and human and environmental sampling. Primary outcomes will be evaluated in children under 5 years of age and include prevalence and diversity of gastrointestinal pathogens, abundance and diversity of antimicrobial resistance (AMR) genes in gastrointestinal microorganisms and markers of gastrointestinal inflammation. Diverse secondary outcomes include changes in microbial contamination; abundance and diversity of pathogens and AMR genes in environmental samples; impacts on ecological biodiversity and microclimates; mosquito vector abundance; anthropometric assessments, nutrition markers and systemic inflammation in children; caregiver-reported and self-reported health symptoms and healthcare utilisation; and measures of individual and community psychological, emotional and economic well-being. The study aims to provide proof-of-concept evidence to inform policies on upgrading of informal settlements to improve environments and human health and well-being. Ethics Study protocols have been approved by ethics boards at Monash University, Fiji National University and Hasanuddin University. Trial registration number ACTRN12618000633280; Pre-results.
UR - http://www.scopus.com/inward/record.url?scp=85099230771&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85099230771&partnerID=8YFLogxK
U2 - 10.1136/bmjopen-2020-042850
DO - 10.1136/bmjopen-2020-042850
M3 - Article
C2 - 33419917
AN - SCOPUS:85099230771
SN - 2044-6055
VL - 11
JO - BMJ Open
JF - BMJ Open
IS - 1
M1 - e042850
ER -